Business Context and Reporting Period
Company: PowerUp Acquisition Corp. (Note: The filing metadata references "Aspire Biopharma Holdings, Inc.", but the document text identifies the registrant as PowerUp Acquisition Corp., a Cayman Islands exempted company and Special Purpose Acquisition Company (SPAC). Aspire Biopharma, Inc. is the target of a proposed business combination.)
Reporting Period: Quarter ended September 30, 2024.
Business Overview: The Company is a blank check company formed to effect a merger, share exchange, or asset acquisition. It has not commenced operations and generates no operating revenue. Its primary activity is searching for a target business. The Company has until February 17, 2025, to consummate an initial Business Combination or face liquidation.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2024 | Nine Months Ended Sept 30, 2024 | Balance Sheet (Sept 30, 2024) |
|---|---|---|---|
| Operating Expenses | $630,772 | $3,654,462 | - |
| Net Loss | $(537,019) | $(3,606,378) | - |
| Trust Account Balance | - | - | $6,601,357 |
| Operating Cash Flow | - | $(2,826,804) | - |
| Working Capital Deficit | - | - | $(6,511,072) |
| Total Liabilities | - | - | $6,572,881 |
| Redeemable Shares (Temporary Equity) | - | - | $6,601,357 |
Debt and Liquidity: The Company has $0 in its operating bank account. Current liabilities include approximately $4.9 million in Subscription Agreement loans and $436,000 in Loan and Transfer notes payable. The Company relies on the Trust Account for potential redemption or business combination funding.
Material Changes vs. Prior Period
- Net Loss vs. Net Income: The Company reported a net loss of $3.6 million for the nine months ended September 30, 2024, compared to a net income of $4.6 million for the same period in 2023. The 2023 income was driven by significant interest income ($5.55 million) from the Trust Account, whereas 2024 interest income was only $481,511 due to lower interest rates and a reduced Trust balance.
- Operating Expenses: Operating expenses increased significantly to $3.65 million in the first nine months of 2024 from $937,554 in 2023. This increase includes a $2 million expense related to the terminated Visiox Merger Agreement.
- Trust Account Reduction: The Trust Account balance decreased from $19.9 million at December 31, 2023, to $6.6 million at September 30, 2024. This reduction is primarily due to shareholder redemptions totaling approximately $13.8 million in May 2024.
- Share Count: Shares subject to possible redemption decreased from 1.8 million to 577,644 following the May 2024 redemption event.
Outlook, Risks, and Management Commentary
- Business Combination Status: The Company terminated its merger agreement with Visiox Pharmaceuticals on July 19, 2024, due to unsatisfied closing conditions. Subsequently, on August 26, 2024, the Company entered into a new merger agreement with Aspire Biopharma, Inc. Amendments to this agreement were made in September and October 2024 to adjust consideration and extend due diligence timelines.
- Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time (one year from issuance). The Company has a working capital deficit and $0 in operating cash. It may need to raise additional capital through loans or investments to fund operations and complete a business combination.
- Liquidity Risk: The Company has until February 17, 2025, to complete a transaction. If no extension is approved by shareholders, the Company must liquidate and redeem public shares.
- Internal Controls: The Company identified a material weakness in internal controls over financial reporting related to debt discount amortization and debt reporting during the quarter.
- Unusual Items: A $2 million expense was recognized in the nine months ended September 30, 2024, related to the Visiox transaction. Additionally, fair value adjustments on Subscription Agreement loans and Loan and Transfer notes resulted in significant non-cash charges.
Investor Verification Checklist
- Merger Progress: Verify the current status of the Aspire Biopharma merger, specifically whether the conditions for closing have been met or if further extensions are required.
- Liquidity Runway: Confirm the Company's ability to fund operations until February 17, 2025, given the $0 operating cash balance and significant working capital deficit.
- Debt Obligations: Review the terms of the $4.9 million Subscription Agreement loan and $436,000 in related party notes, including conversion features and repayment triggers.
- Redemption Risk: Assess the likelihood of further shareholder redemptions which could further deplete the Trust Account below the minimum cash condition required for the Aspire merger.
- Internal Controls: Monitor the remediation plan for the identified material weakness in financial reporting controls.